UBS lifts target for Madrigal Pharmaceuticals stock to USD 735.00

Published on 10/15/2026 at 22:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Madrigal's next earnings date is November 3, 2026. Madrigal Pharmaceuticals stock costs EUR 410.05 on October 15, 2026 at 10:03 p.m. CEST.

UBS target and reporting date

UBS raised its Madrigal target from USD 669.00 to USD 735.00 on October 14, 2026.
Madrigal's next estimated earnings date is November 3, 2026.
Madrigal Pharmaceuticals stock costs EUR 410.05 at Lang & Schwarz on October 15, 2026 at 10:03 p.m. CEST.
Madrigal had a USD 10.6 billion market capitalization on October 15, 2026.

MDGL, US5588681057, Illustration mit AI erstellt.

UBS raised its price target for Madrigal Pharmaceuticals (ISIN US5588681057) from USD 669.00 to USD 735.00 on October 14, 2026, while keeping a Buy rating, according to Investing.com. Against the USD 459.81 Nasdaq quote at 4:00 p.m. ET on October 15, 2026, the new target stands 59.85 percent above the stock price. Madrigal Pharmaceuticals stock was trading at EUR 410.05 at Lang & Schwarz on October 15, 2026 at 10:03 p.m. CEST.

November 3 earnings date

The next scheduled reporting date is November 3, 2026. MarketBeat lists that date as Madrigal's next estimated earnings release, following the company's second-quarter report on July 30, 2026.

Range and trading position

Madrigal's Nasdaq 52-week range was USD 393.61 to USD 615.00 as of October 15, 2026. The USD 459.81 quote stood 16.82 percent above the low and 25.23 percent below the high, leaving the stock materially closer to its yearly low than its yearly high.

Trading activity also remained below the recent average. Volume was 259,074 shares against an average of 294,510 shares on October 15, 2026, while the company's market capitalization was USD 10.6 billion.

Valuation and business scale

The trailing P/E ratio was negative 35.67 on October 15, 2026, reflecting the company's reported losses rather than a positive earnings multiple. Madrigal's latest reported second-quarter 2026 revenue was USD 364.25 million, but that figure was already used as the core of an earlier company article and is included here only as dated background.

Madrigal focuses on therapies for metabolic dysfunction-associated steatohepatitis and identifies Rezdiffra as its first approved therapy, according to the company's Madrigal Pharmaceuticals investor-relations page. The scheduled November date gives the next results release a clear place on the calendar, while the UBS target keeps attention on expectations for the company's F4 program.

Euro quote and market value

The euro quotation from Lang & Schwarz stood at EUR 410.05 on October 15, 2026 at 10:03 p.m. CEST. Madrigal's U.S. listing was at USD 459.81 on Nasdaq at 4:00 p.m. ET on the same date, and the company had a USD 10.6 billion market capitalization.

The further course of trading is shown by the continuously updated real-time quote of Madrigal Pharmaceuticals stock.